Skip to main content

Table 4 Overall Best Response Per RECIST V 1.1 and for Patients with Metformin Duration of > 5 Months (PR = Partial Response, CR = Complete Response, SD = Stable Disease, PD = Progressive Disease, ORR = Objective Response Rate, DCR = Disease Control Rate)

From: Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma

All Patients

No Metformin N = 33 (60%)

Metformin N = 22 (40%)

 

Best Response

 PR

14 (42.4%)

9 (40.9%)

P = 0.39

 CR

4 (12.1%)

6 (27.27%)

 SD

2 (6%)

2 (9.1%)

 PD

13 (39.4%)

5 (22.7%)

ORR

54.5%

68.2%

P = 0.31

DCR

60.6%

77.3%

P = 0.19

Median Time to Achieve Best Response (months)

2.7

2.8

P = 0.12

Metformin Duration of > 5 Months

No Metformin N = 33 (67.3%)

Metformin N = 16 (32.7%)

 

Best Response

 PR

14 (42.4%)

5 (31.2%)

P = 0.12

 CR

4 (12.1%)

6 (37.5%)

 SD

2 (6%)

2 (12.5%)

 PD

13 (39.4%)

3 (18.8%)

ORR

54.5%

68.7%

P = 0.34

DCR

60.6%

81.3%

P = 0.14

Median Time to Achieve Best Response (months)

2.7

3

P = 0.11